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Abstract: Since terbinaﬁ  ne was introduced on the world market 17 years ago, it has become 
the leading antifungal for the treatment of superﬁ  cial fungal infections, aided by unique pharma-
cologic and microbiologic proﬁ  les. This article reviews mode of action, antimycotic spectrum 
and disposition proﬁ  le of terbinaﬁ  ne. It examines the data, accumulated over 15 years, on the 
comparative efﬁ  cacy of terbinaﬁ  ne (vs griseofulvin, itraconazole, ﬂ  uconazole) in the management 
of the infections for which it is primarily indicated (eg, dermatophytoses) and provides a brief 
discussion on its use for the treatment of non-dermatophyte infections. Finally, the available 
data on the newest topical and systemic formulations are introduced.
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Introduction
In 2008, oral terbinaﬁ  ne reached the 12-year mark in the United States (US) and 
17 years on the world market. Since its launch, terbinaﬁ  ne has garnered the top slot 
among topical antifungals and the oral formulation is estimated to have captured nearly 
80% of the greater than US$1.5 billion worldwide onychomycosis market (although it 
makes up only a minority of prescriptions written for children).1,2 Terbinaﬁ  ne remains 
the only commercially available orally available allylamine and shares the topical 
allylamine/benzylamine market with naftiﬁ  ne, butenaﬁ  ne and amorolﬁ  ne. In recent 
years several new formulations have been added to the portfolio of this antimycotic 
including a pediatric oral granule approved by the US Food and Drug Administration 
in September of 2007 and a single-dose, ﬁ  lm-forming topical solution that is now 
available over the counter in a number non-US markets.
This article will review the accumulated data on the mycology and pharmacology 
of terbinaﬁ  ne including its mode of action, antimycotic spectrum, disposition proﬁ  le 
and therapeutic efﬁ  cacy. The primary focus will surround dermatophytoses with a brief 
discussion on the role, to date, of terbinaﬁ  ne in non-dermatophyte infections.
Clinical mycology
Discovered in 1983, terbinaﬁ  ne is a member of the allylamine class of antifungals. It 
differs from its parent compound, naftiﬁ  ne, by the presence of a tert-butyl acetylene 
substitution of the phenyl ring on the side chain of the molecule. This substitution 
confers an increase in oral efﬁ  cacy and an additional 10 to 100 times the in vitro 
activity of naftiﬁ  ne.3,4
Terbinaﬁ  ne inhibits fungal growth by disrupting sterol biosynthesis. It abrogates 
the formation of ergosterol by inhibiting squalene epoxidase, the catalytic enzyme 
responsible for converting squalene to 2,3-oxidosqualene (an ergosterol precursor). 
The resultant deﬁ  ciency in ergosterol compromises cell wall integrity and contrib-
utes to impaired growth and/or death of the pathogen.5–7 Notably, the biosynthesis 
of cholesterol in higher order eukaryotes similarly relies on the activity of squalene Clinical, Cosmetic and Investigational Dermatology 2009:2 50
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epoxidase; however, terbinaﬁ  ne demonstrates a markedly 
lower binding afﬁ  nity for the mammalian enzyme. In vitro, 
the minimum concentration of terbinaﬁ  ne required to inhibit 
95% of squalene epoxidase activity (IC95) is two to three 
orders of magnitude greater for the mammalian enzyme 
(300 μM) than for enzymes isolated from pathogenic yeast 
(0.6–2.1 μM).7
While the majority of clinical terbinaﬁ  ne use is observed 
with infections caused by dermatophytes, the susceptibility 
of numerous organisms including pathogenic yeast, dematia-
ceae, thermally dimorphic fungi and hyaline hyphomycetes 
has been evaluated.8–16 Although the nature of the assays 
employed precludes direct comparison of minimum inhibi-
tory concentrations (MICs) between studies (ie, some were 
performed prior to standardization of a reference method 
by the Clinical and Laboratory Standards Institute (CLSI),17 
some universal trends are repeated throughout. Namely, 
terbinaﬁ  ne demonstrates the greatest activity against species 
within the Trichophyton, Microsporum, and Epidermophyton 
genera followed by the dematiaceae, the ﬁ  lamentous fungi 
and a few selected pathogenic yeast.
The terbinaﬁ  ne MICs observed against the dermatophytes 
are typically several orders of magnitude lower than those 
reported for other fungi.18–23 This heightened susceptibility 
is reﬂ  ected by an MIC that is an order of magnitude lower 
than IC95 for sterol biosynthesis.6 Given that dermatophyte 
growth can be fully inhibited despite only partial inhibi-
tion of sterol synthesis, the activity of terbinaﬁ  ne is likely 
accounted for by other processes including the intracellular 
accumulation of squalene.3 In contrast, the MIC to IC95 ratio 
for several species of fermentative yeast equals or exceeds 
one.6 Compared with dermatophytes, these organisms have 
adapted to survive under anaerobic growth conditions 
which are characterized by low ergosterol and high squalene 
concentrations.6 Reasonably, it is expected that such organ-
isms would be less susceptible to the effects of a squalene 
epoxidase inhibitor.
The MICs reported for terbinaﬁ  ne against various derma-
tophytes are typically comparable to or lower than those of 
other antifungals active against these organisms, namely the 
triazoles, imidazioles and griseofulvin.24 However, a direct 
comparison of MICs between therapeutic agents needs to be 
considered in the context of achievable concentrations at the 
site of infection. No signiﬁ  cant differences in terbinaﬁ  ne sus-
ceptibilities exist between US and non-US isolates of selected 
Trichophyton and Microsporum species.25 Further, the 
putative increase in resistance to azole antifungals observed 
with the “heartier” arthroconidia of the dermatophytes has 
not been observed with terbinaﬁ  ne. Both arthroconidia and 
microconidia of selected Trichophyton species demonstrate 
the same susceptibility proﬁ  le to terbinaﬁ  ne in vitro.26
In addition to diminished susceptibility, non-dermatophyte 
species of fungi demonstrate resistance mechanisms not 
observed in the dermatophytes. Under the selective pressure 
of terbinaﬁ  ne exposure, an increase in the expression of 
energy-dependent efﬂ  ux transporters can be observed in 
yeast;27 however, the expression level of orthologous trans-
porters remains unchanged in dermatophytes.28 Similarly, 
ﬁ  lamentous fungi can upregulate the expression of an enzyme 
that catalyzes the breakdown of terbinaﬁ  ne29 but this has not 
been reported for dermatophytes.
Overall, an extremely low rate of spontaneous mutation 
conferring resistance of dermatophytes to terbinaﬁ  ne exists 
in vitro.30 Nonetheless, reduced susceptibility to terbinaﬁ  ne 
has been observed in clinical dermatophyte isolates. These 
appear to arise from clones harboring one of two described 
sequence variations in the squalene epoxidase gene.31,32 As 
the reported mutations do not appear to impact fungal growth 
in the absence of terbinaﬁ  ne,33 they likely signal changes to 
the terbinaﬁ  ne binding domain and ultimately binding afﬁ  nity 
of the drug for the protein.34
While spontaneous resistance is rare, increasing reports 
describe cross-resistance developing between other anti-
fungals and terbinafine. Under the selective pressure 
of echinocandin exposure in vitro, the upregulation of 
efﬂ  ux transporters in yeast also reduced susceptibility to 
terbinaﬁ  ne.35 Similarly, azole “pre-exposure” in yeast can 
diminish susceptibility of the organisms to terbinaﬁ  ne.36–38 
Notably, the aforementioned mechanisms of cross-resistance 
have not been reported for dermatophytes, in vitro or in vivo, 
after protracted imidazole treatment.36–38
Of potentially signiﬁ  cant clinical relevance is the activity 
of terbinaﬁ  ne when used in combination with other anti-
fungals for the management of invasive mycoses. Against 
Aspergillus fumigatus, indifference was primarily observed 
when terbinaﬁ  ne was combined with amphotericin B. Simi-
larly, terbinaﬁ  ne did not improve the activity of ﬂ  uconazole 
or itrazonazole against A. fumigatus; however, the triazoles 
demonstrated synergism when added to terbinaﬁ  ne.39 Against 
ﬂ  uconazole-resistant yeast, synergy with ﬂ  uconazole and 
itraconazole was observed in a fraction of isolates, Candida 
glabrata  Candida tropicalis,  Candida kreusi.40,41 In 
these pathogenic yeast antagonism has also been observed 
among these antifungals.41 Against ocular isolates of 
Fusarium, the combination of amphotericin B and terbinaﬁ  ne 
was synergistic, while the combination of terbinaﬁ  ne and Clinical, Cosmetic and Investigational Dermatology 2009:2 51
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triazoles demonstrated indifference.42 The ultimate utility 
of terbinaﬁ  ne in the management of invasive infections will 
be determined as more experience is obtained utilizing this 
agent as adjunct therapy.
Clinical pharmacology 
(Tables 1 and 2)
Terbinaﬁ  ne is efﬁ  ciently absorbed following oral administration 
(bioavailability approx. 70%) and this does not appear to be 
affected by feeding status.51,52 Over the range of clinically 
relevant doses (125–750 mg) terbinaﬁ  ne demonstrates a linear 
absorption proﬁ  le with total body exposure increasing in direct 
proportion to dose.53 The rate of absorption does not appear 
to differ substantially between children and adults. However, 
the extent of absorption as reﬂ  ected by maximum plasma 
concentrations is markedly lower in children when doses are 
normalized per kilogram of body weight.43
Following topical administration to normal skin, cream- and 
gel-based terbinaﬁ  ne formulations attain concentrations rang-
ing from 746 to 949 ng/cm2.48,54 Maximum stratum corneum 
concentrations increase by 15% with 7 days of application; 
however, the area under the plasma concentration vs time curve 
(AUC) can increase by as much as 40% over 1 week.54 Notably, 
concentrations obtained in the horny layer of patients with an 
active infection can be up to an order of magnitude lower than 
that observed in healthy individuals.55 While topical prepara-
tions are well absorbed into the stratum corneum, the resultant 
systemic exposure is several orders of magnitude lower than 
observed after oral terbinaﬁ  ne administration (Tables 1 and 2).
Terbinafine is extensively distributed with estimates 
of apparent distribution volume approaching 20 L/kg.53,56 
This relatively large volume of distribution results from the drugs 
high degree of lipophilicity, extensive protein binding proﬁ  le 
and ability to concentrate in adipose and keratin rich tissue.56,57 
At steady-state, concentrations observed in sebum, stratum 
corneum and hair exceed those observed in the plasma by as 
much as an order of magnitude. Although lower in the stratum 
corneum of hyperkeratotic tissue, terbinaﬁ  ne concentrations 
remain elevated following the discontinuation of oral therapy 
and persist in excess of 1 month after stopping treatment.58
At least seven cytochromes P450 (CYP) appear to be 
responsible for metabolizing terbinaﬁ  ne into more than 
15 metabolites.59 In adults, the N-demethyl and carboxybutyl 
metabolites constitute the largest fraction of the metabolites 
observed. Maximum circulating concentrations and total body 
exposure are comparable or in excess of those observed with 
the parent compound. Notably, the circulating half-life for the 
carboxy metabolites were twice as long as that of terbinaﬁ  ne.46 
Although the metabolites lack an appreciable antifungal 
activity, they may contribute to the drug interactions and/or 
side effects observed following administration.51,60
Given the polyfunctional nature of terbinafine as a 
substrate for the CYP450, the magnitude of potential drug 
interactions would be predicted to be low as compared with 
other drugs.61–63 However, this is not the case for interactions 
mediated by CYP2D6. Terbinaﬁ  ne exhibits potent inhibition 
of this enzyme in vitro (apparent inhibitor rate constant (ki) 
approx. 30 nM) and correspondingly marked reduction in 
the metabolism of the CYP2D6 substrate dextromethorphan 
in vivo.60,64 Importantly, the activity of CYP2D6 may not return 
to normal for months after the completion of a prolonged 
course of therapy.64 Clinically, terbinaﬁ  ne is demonstrated to 
interact with concurrently administered CYP2D6 substrates 
including amitriptyline, nortriptyline, desipramine, and 
Table 1 Pharmacokinetic parameter estimates of terbinaﬁ  ne following oral administration
Parametera Adults 125 mg 
single-dose 
(n = 26)43,44
Adults 250 mg 
single-dose 
(n = 29)45,46
Adults 125 mg 
steady-state 
(n = 10)43




125 mg single-dose 
(n = 28)43,44
Children 125 mg 
steady-state 
(n = 16)43
Tmax (h) 1.3–1.5 1.4–1.5 1.6 1.2 1.7–2.1 1.8
Cmax (ng/mL) 506–565 1340–1656 646 1700b 706–909 1059
AUC (h*ng/mL) 1624–2135 4740–6762 3720 10481 2967–4104 5851
Cl/F (L/h/kg) 1.2 0.55 0.4 1.9 1.7
Vss/F (L/kg) 19.2 19.5
t1/2α (h) 0.7 0.35 1.2
t1/2β (h) 26.7 12.6–14.2 14.7
t1/2γ (h) 396 156
Notes: aValues represent the mean reported values from the referenced studies (when more than one study is referenced, values represent the range of reported mean 
values). bCorresponding peak tissue concentrations: hair, 2.4 μg/g; stratum corneum, 14.4 μg/g; sebum, 56.1 μg/g.
Abbreviations: T max, time at maximum plasma concentration; Cmax, maximum plasma concentration; AUC, area under the plasma concentration vs time curve; Cl/F, apparent 
oral clearance;   Vss/F, steady-state volume of distribution; t1/2α, alpha-phase half-life; t1/2β, beta-phase half-life, t1/2γ,  gamma-phase or terminal half-life.Clinical, Cosmetic and Investigational Dermatology 2009:2 52
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venlafaxine.65–68 Other drugs harboring the potential to interact 
with terbinaﬁ  ne include perphenazine, metoprolol, encainide 
and propafenone.69
For drugs that are not substrates of CYP2D6 (eg, anti-
coagulants, corticosteroids, oral contraceptives, tolbuta-
mide, cyclosporine, midazolam, digoxin and terfenadine) 
terbinaﬁ  ne has only a modest or minimal affect on their 
metabolism.70–74 However, as a substrate of the cytochromes 
P450, the pharmacokinetics of terbinaﬁ  ne are altered with the 
concurrent administration of several agents (eg, cimetidine, 
terfenadine, rifampin).70,75
The clearance of terbinaﬁ  ne is triphasic with the terminal 
elimination half-life approximating 100 hours after a single 
dose and 22 days with durations of therapy spanning several 
months.44,76 Approximately 80% of terbinaﬁ  ne’s metabo-
lites are excreted by the kidney with the remaining fraction 
eliminated in the feces.44 This protracted rate of elimination 
accounts for the magnitude of accumulation observed with 
terbinaﬁ  ne after repeated dosing and the persistence in plasma 
and tissues long after discontinuation of the drug.47 While 
this confers a distinct advantage to the allylamine permitting 
shorter courses of therapy, it poses a unique disadvantage for 
patients experiencing drug-related adverse events.
Therapeutic use
Terbinafine is indicated for use in the management of 
cutaneous dermatophytoses (eg, tinea corporis, tinea cruris 
and tinea pedis), onychomycosis and most recently tinea 
capitis. In addition, terbinaﬁ  ne use has been explored in 
a number of superﬁ  cial and systemic mycoses involving 
pathogens other than the dermatophytes. The results of open-
label and randomized trials exploring the utility of terbinaﬁ  ne 
in various infections is detailed in the following sections.
Cutaneous dermatophytoses
Dermatophyte infections of the glabrous skin, groin and feet 
can be caused by any of a number of dermatophyte species.77 
While these infections typically respond to topical antifungals, 
oral therapy is often indicated when the lesions are widespread 
or chronic in nature.78
Terbinaﬁ  ne applied topically as a 1% cream, gel or solu-
tion demonstrates utility in the management of both tinea 
corporis and tinea cruris.79 The application of terbinaﬁ  ne 
once-daily for 7 to 14 days resulted in mycological cure rates 
ranging from 84% to 94%, clinical cure rates ranging from 
75% to 84% and overall efﬁ  cacy rates ranging from 65% 
to 83%;80–86 The observed treatment response with topical 
terbinaﬁ  ne is signiﬁ  cantly greater than reported for placebo 
wherein clinical, mycological and complete cure rates range 
from 8% to 22%.81,83 Topically applied terbinaﬁ  ne also dem-
onstrated statistically greater mycological response rates than 
a 2-week course of 2% ketoconazole cream,80 whereas clinical 
response rates were comparable to a 0.6% gel containing the 
garlic-derived, sulfuric compound ajoene.84
Following oral administration for the treatment of tinea 
corporis and tinea cruris, clinical and mycological cure rates 
observed with terbinaﬁ  ne have ranged from 71% to 100% and 
78% to 100%, respectively.78,87–89 No signiﬁ  cant differences 
in mycological or clinical cure rates were observed between 
terbinaﬁ  ne and griseofulvin in these studies;87–89 however, 
higher relapse rates were observed with griseofulvin.88,89 
Tinea imbricata, a variant of tinea corporis found predomi-
nantly in tropical countries, manifests as concentric rings 
of papular plaques that are chronic in nature and relatively 
recalcitrant to antifungal therapy. In a single random-
ized, controlled trial 4 weeks of treatment with terbinaﬁ  ne 
demonstrated higher overall efﬁ  cacy rates (100%) and lower 
relapse rates (16%) as compared with itraconazole (89% 
efﬁ  cacy, 75% relapse).90
Tinea pedis is a dermatophyte infection of the foot that 
generally takes one of three forms: 1) interdigital infections 
characterized by cracking and ﬁ  ssuring of the skin in the 
webbing between the toes, 2) acute vesicular infections 
which present with erythema, bullous eruptions and bacterial 
Table 2 Local and systemic estimates of exposure following topical terbinaﬁ  ne application




1% FFS 1 
application50
Stratum corneum Cmax (μg/cm2) 0.91 0.94–2 5
Stratum corneum AUC (h*μg/cm2) 12.7 11.7–13.5 104.2
Tissue t1/2 (h) 1.2 68 162
Plasma Cmax (ng/mL) 3.82
Plasma AUC (h*ng/mL) 63
Notes:   aValues represent the mean reported values from the referenced studies (when more than one study is referenced, values represent the range of reported mean values).
Abbreviations: Cmax, maximum observed concentration,   AUC, area under the concentration vs time curve; t1/2, half-life.Clinical, Cosmetic and Investigational Dermatology 2009:2 53
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super-infections and 3) a chronic form of infection with 
scaling that covers the entire foot typically referred to as 
“dry” or “moccasin” type tinea pedis.91 The nature and 
extent of infection often determines whether oral therapy 
is required or whether symptomatic relief can be obtained 
with topical therapy.92
Although topical terbinaﬁ  ne formulations in excess of 
1% have been investigated, superﬁ  cial treatment of tinea 
pedis typically relies on 5 to 7 days of application with the 
1% cream, gel or solution (as described above for infections 
of the skin and groin). Mycologic cure rates are comparable 
irrespective of formulation, ranging from 82% to 97% with 
overall efﬁ  cacy rates of 64% to 86%. Response rates are 
signiﬁ  cantly greater than observed with the vehicle alone 
wherein mycologic cure and overall efﬁ  cacy range from 22% 
to 37% and 4% to 26%, respectively.83,93–96 Mycological cure 
rates, after 1 week of treatment, are also comparable to or 
greater than those observed after 4 weeks of treatment with 
topical azole preparations.97–99
Despite the advantage of a strong efﬁ  cacy proﬁ  le with 
the application of terbinaﬁ  ne for one week, efforts to sim-
plify topical administration, decrease treatment duration and 
improve compliance has lead to the development of a poly-
meric ﬁ  lm-forming solution (FFS) designed as a “one-time” 
dose. The acrylate/cellulose/triglyceride based formulation 
leaves a nearly invisible, highly-concentrated ﬁ  lm on the 
skin after the carrier solvent (ethanol) has evaporated. This 
ﬁ  lm remains on the site of infection nearly 6 times longer 
than other topical preparations and results in stratum cor-
neum concentrations that are sustained above the MIC in 
excess of 2 weeks after application.50,100 FFS concentrations 
as high as 10% have been evaluated; however, mycologi-
cal cure rates (80%–84%) and overall efﬁ  cacy (61%–70%) 
6 weeks after application did not appear to demonstrate 
dose-dependence.100 Consequently, the currently marketed 
formulation contains 1% terbinaﬁ  ne. In a study examining 
slightly longer-term follow-up, mycological cure rates were 
observed in 72% of those treated. Notably, the duration of 
infection prior to treatment did not appear to inﬂ  uence the 
likelihood of mycological cure. When participants were 
re-evaluated at 3 months, 12.5% of those individuals consid-
ered mycologically cured at 6 weeks demonstrated positive 
cultures, comparable to the rates observed with other topical 
terbinaﬁ  ne formulations.101
For more refractory (eg, hyperkeratotic) infections of the 
foot, efﬁ  cacy rates comparable to those described above can 
be observed with topical treatment; however, this may require 
protracted treatment durations (ie, several months).55 In these 
cases, oral therapy has emerged as a reliable alternative. 
Orally administered terbinaﬁ  ne can be highly effective in 
the management of tinea pedis with overall efﬁ  cacy rates 
exceeding 90% depending on the nature of infection and the 
regimen used. The majority of investigations have examined 
the efﬁ  cacy of orally administered terbinaﬁ  ne at daily doses 
of 250 mg (either divided or once daily). Efﬁ  cacy rates after 
6 weeks of treatment ranged from 59% to 75%, increasing to 
65% to 88% 12 weeks after the end of therapy.102,103 This is 
compared with placebo and griseofulvin where efﬁ  cacy rates 
were 0% and 27%, respectively at the end of treatment and 
0% and 45%, respectively, 2 weeks post treatment.102,103 With 
shorter courses of oral treatment (250 mg daily × 2 weeks), 
mycological and clinical cure rates are markedly less impres-
sive (23%–28% and 8%–43%, respectively). However, 
when followed out for 6 to 16 weeks, mycological cure 
rates (78%–86%) and clinical efﬁ  cacy (71%–94%) improve 
dramatically suggesting utility with shorter treatment dura-
tions of terbinaﬁ  ne.104,105 Cure rates observed with terbin-
aﬁ  ne were comparable to those observed with itraconazole 
(100 mg/day); however, long-term follow-up suggested that 
terbinaﬁ  ne was slightly superior to 4 weeks of itraconazole 
treatment and signiﬁ  cantly superior to 2 weeks of treatment 
with the triazole.104,105 Data from a single study each suggest 
that reducing (125 mg/day) or increasing (500 mg/day) the 
dose of terbinaﬁ  ne may not substantially alter cure rates 
compared traditional dosing with 250 mg/day.51,58
Onychomycosis
Approximately one-half of all nail problems are accounted 
for by onychomycosis, a fungal infection wherein the nails 
become discolored, thickened and prone to peeling or 
splitting.106 Dermatophytes are principally responsible for 
infections of the toenail, whereas over 50% of ﬁ  ngernail 
infections can be caused by non-dermatophyte species.107,108 
Of the commercially available oral antifungals, griseofulvin, 
itraconazole and terbinafine are most commonly used 
for the management of onychomycosis. Efficacy rates 
and treatment durations vary although treatment with the 
latter agents typically requires shorter courses than does 
the former. Irrespective, the majority of studies described 
below document cure rates at 12 months or beyond (earlier 
for ﬁ  ngernails) to account for the protracted growth rate of 
nails and the extended time-frames over which drug remains 
in the affected nails.
Since its approval, scores of studies have evaluated 
numerous terbinaﬁ  ne dosing regimens for the treatment of 
onychomycosis. With the administration of daily 250 mg Clinical, Cosmetic and Investigational Dermatology 2009:2 54
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doses, mycologic and clinical response rates observed 
in toenails ranged from 72% to 92% and 45% to 77%, 
respectively.109–113 Notably, there was little difference in both 
clinical and mycological response rates whether patients 
were treated for 12, 18 or 24 weeks.109,111–113 Infections of the 
ﬁ  ngernail demonstrated comparable response rates ranging 
from 71% to 100%.109,111,114 When non-dermatophyte patho-
gens are considered in subgroup analyses, response rates 
approximate 40% for infections with Candida and greater 
than 90% when treating Scopulariopsis brevicaulis.115–117 
The combination of daily terbinaﬁ  ne doses (250 mg) with 
chemical or mechanical removal of the nail offers little to 
no additional increase in efﬁ  cacy over terbinaﬁ  ne alone.118,119 
Similarly, only limited increases in efﬁ  cacy are observed 
when daily oral therapy is combined with adjunctive therapy 
including once-weekly topical amorolﬁ  ne or once-daily topi-
cal ciclopirox.120–123 In each study topical therapy appeared 
to confer slight improvements in response; however, limited 
sample sizes restrict their signiﬁ  cance and superiority over 
terbinaﬁ  ne alone could not be determined.
Intermittent terbinaﬁ  ne dosing has also been explored 
for the management of onychomycosis. When the standard 
regimen of 250 mg once daily was compared to intermittent 
dosing administered at 350 mg daily for 2 weeks followed 
by 2 weeks “off  ” for the management of subungual 
onychomycosis, both mycological (56%–58% vs 43%–50%) 
and complete cure (26%–30% vs 20%–24%) favored 
traditional dosing; however, only the latter was statistically 
signiﬁ  cant.124 When compared with 500 mg administered 
daily for 1 week (followed by 3 weeks off) for the treatment 
of distal subungual onychomycosis, traditional dosing again 
proved superior to intermittent dosing. Mycological cure of 
the target toenail (71% vs 59%); clinical cure of the target 
toenail (45% vs 29%); complete cure of the target toenail 
(40% vs 28%); and complete cure of all 10 toenails (25% vs 
15%) were all statistically greater with standard dosing.125 No 
signiﬁ  cant differences in complete cure have been observed 
based on the number of pulses administered; however, a clear 
trend is noted with response rates increasing steadily from 
one to four pulses.126 As noted with traditional dosing, higher 
cure rates were observed for ﬁ  ngernails treated with pulse-
dosing as compared with toe nails. Mycological and clinical 
cure rates were 89% and 72% for dermatophytes, albeit lower 
(67%) for infections caused by yeast.127 As expected based 
on the comparative data generated from traditional dosing 
trials, the combination of pulse therapy with ancillary topical 
therapy does not substantially improve outcome over treat-
ment with terbinaﬁ  ne alone.126–128
In two comparative trials, terbinafine (250 mg/day) 
was significantly superior to griseofulvin (500 mg/day). 
Mycological cure rates were significantly higher with 
terbinaﬁ  ne (84%–92% vs 45%–63%), time to mycological 
cure significantly shorter (73 vs 93 days) and clinical 
cure significantly higher (76% vs 39%) as compared 
with griseofulvin.129,130 However, the exclusion of non-
dermatophyte pathogens in one study and the administration 
of sub-clinical griseofulvin doses in both studies likely resulted 
in an overestimate of terbinaﬁ  ne’s superiority. In a single trial 
employing the recommended dose of griseofulvin (1000 mg 
daily) mycological response was similar between terbinaﬁ  ne 
and griseofulvin (88% vs 82%, respectively); however, clinical 
response at the end of study was greater with terbinaﬁ  ne (81% 
vs 62%). Not surprisingly time to negative mycologic cultures 
was shorter for terbinaﬁ  ne (130 days vs 172 days).131
In three studies, traditional dose itraconazole (200 mg/day) 
was compared with traditional dose terbinaﬁ  ne (250 mg/day). 
In only one investigation where infections were solely restricted 
to those caused by dermatophytes did mycological cure rates 
favor terbinaﬁ  ne (81%–92% vs 63%–67%). In the remaining 
investigations no difference in mycological cure rates were 
observed between the allylamine and the triazole.132–134 The 
remainder of studies comparing the two agents examined 
pulse-dosing of itraconazole. In the treatment of distal and 
lateral subungual onychomycosis restricted to dermatophytes, 
no appreciable difference was observed between itracon-
azole (400 mg/day one week “on” three weeks “off  ”) and 
terbinaﬁ  ne (mycological cure rates: 75%–90% vs 76%–87%, 
clinical cure rates 53%–82% vs 50%–79%).135–138 Not surpris-
ingly, itraconazole demonstrated superior cure rates among 
the non-dermatophyte moulds (62% vs 44%) and Candida 
species (92% vs 40%).138 These studies are contradicted by 
a large multi-national trial wherein mycological cure rates 
at 18 months were significantly greater with terbinafine 
(76%–80%) than observed with pulse-dose itraconazole 
(38%–49%).139 In selected subpopulations, complete cure rates 
observed after 4 years remained superior in the terbinaﬁ  ne 
arm (24%–78%) compared with those receiving itraconazole 
(24%–28%) as did mycological cure (46% vs 13%).140,141
Finally, two investigations compare daily terbinaﬁ  ne 
with once weekly fluconazole (150 mg). Clinical cure 
rates (21%–38% vs 67%–81%), mycological cure rates 
(31%–51% vs 75–89%) and overall efﬁ  cacy (31% vs 62%) 
were inferior in ﬂ  uconazole treated patients.135,142
Despite reasonable efﬁ  cacy rates, the results of numerous 
trials indicate that a substantial fraction of onychomycosis 
patients treated with terbinaﬁ  ne remain uncured at the end Clinical, Cosmetic and Investigational Dermatology 2009:2 55
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of treatment. Consequently several investigations have 
attempted to address whether additional intrinsic or extrinsic 
factors inﬂ  uence treatment response. Although the majority 
of these investigations were not adequately powered to deﬁ  ni-
tively determine an association between selected covariates 
and treatment failure, several trends could be observed. The 
studies suggested that a higher fraction of patients 1) receiv-
ing lower terbinaﬁ  ne doses (125 mg vs 250 mg), 2) with distal 
and lateral subungual onychomycosis, 3) with big toenail 
involvement, or 4) with positive mycology 3 months into 
treatment remain uncured at the time of follow-up.143–145 The 
link between other factors such as demographic characteris-
tics, the rate of nail growth, the species of infecting pathogen, 
the extent and duration of disease at the time of presentation 
and the number of nails involved remain unclear.144–146
Tinea capitis
Ringworm of the scalp is a dermatophyte infection commonly 
seen among preschool and school-aged children. It is one of 
the few dermatophyte infections that does not adequately 
respond to topical therapy, often requiring 6 to 8 weeks of 
oral antifungal treatment.147 Griseofulvin remains the gold 
standard in the management of this infection, but treatment 
failures are common and it is not unusual for children to 
remain on therapy for extended durations.148
Several studies have examined the role of terbinaﬁ  ne 
in the treatment of tinea capitis; however, results need to 
be considered in the context of the geographic origin of the 
study participants given that the primary causative organ-
isms and, thus response rates, are expected to vary between 
countries.149–151 The majority of these studies examine a 
weight-based dosing scheme with 62.5 mg of terbinaﬁ  ne 
administered to children under 20 kg, 125 mg administered to 
children between 20 and 40 kg and an adult dose of 250 mg 
administered to children over 40 kg.
With the administration of terbinaﬁ  ne for one week, 
Trichophyton infections are effectively treated in 56% 
of children.152,153 Efﬁ  cacy rates ranged from 69% to 86% 
after 2 weeks of treatment, averaged 65% with 4 weeks 
of treatment and ranged from 80% to 100% after 6 weeks 
of therapy.44,152–155 Corresponding mycological cure rates 
observed after 1, 2, 4 and 6 weeks of treatment were 60%, 
76%, 72% and 90%, respectively.44,152,154 By contrast, 
infections with Microsporum are less responsive to 
terbinaﬁ  ne. Response rates as low as 15% are observed with 
1 to 2 weeks of therapy.153 However, extended durations of 
treatment and/or doubling of the dose appeared to improve 
the likelihood of efﬁ  cacy in children harboring Microsporum 
and clinical and mycological response rates begin to approxi-
mate those observed for Trichophyton.153,156–158
In comparative trials, terbinaﬁ  ne, when used for dura-
tions of 4 weeks, appeared to be as effective as griseofulvin 
administered for slightly longer intervals (8 weeks). Clinical 
and mycological cure rates ranged from 64% to 93% and 
70% to 93%, respectively for terbinaﬁ  ne and 67% to 80% and 
72% to 88%, respectively for griseofulvin.159–161 As above, the 
exception lies with infections caused by Microsporum where 
griseofulvin appears to be superior to terbinaﬁ  ne even when 
the allylamine is administered for 12 weeks.160–162 Pulse regi-
mens wherein the standard dose or double the standard dose 
of terbinaﬁ  ne is administered daily for 1 week (followed by 
3 weeks off) do not appear to confer any advantage or dis-
advantage in the treatment of Microsporum infections over 
standard regimens.163 By contrast, terbinaﬁ  ne appeared to be 
slightly more effective than both itraconazole and ﬂ  uconazole 
in treating tinea capitis.164 It should be noted that in a number 
of the aforementioned studies, the griseofulvin doses employed 
(as low as 6 mg/kg) were markedly lower than those recom-
mended for use in clinical practice. Consequently, the studies 
may have underestimated the efﬁ  cacy of griseofulvin.
A single publication is available detailing the results of two 
randomized-controlled trials that compared 6 weeks of treat-
ment with the recently marketed terbinaﬁ  ne oral granule formu-
lation (5–8 mg/kg daily) with griseofulvin (10–20 mg/kg daily) 
for the management of tinea capitis. The new formulation 
is designed to be sprinkled on foods thereby improving the 
reliability with which the drug can be administered to young 
children (4 years of age). In these investigations, the complete 
cure rate observed with terbinaﬁ  ne was superior to griseofulvin 
in one trial (46% vs 34%) but not the other (44% vs 43%). 
Similarly mycological cure rates were signiﬁ  cantly higher 
in trial 1 (62% vs 50%) but not in trial 2 (61% vs 60%). In 
afﬁ  rmation of the results conferred in previously conducted 
trials, subgroup analyses in these trials revealed that terbinaﬁ  ne 
was signiﬁ  cantly better than griseofulvin when children were 
infected with Trichophyton tonsurans whereas griseofulvin 
proved superior for the treatment of infections with Micros-
porum canis.165 This multi-national study also reported greater 
efﬁ  cacy among US vs non-US infections which was likely 
accounted for by the higher fraction of children in the US that 
are infected with T. tonsurans.
Non-dermatophyte infections
Although not within the scope of this review, we would be 
remiss not to point out the increasing utilization of terbi-
naﬁ  ne, alone and in combination, for the management of Clinical, Cosmetic and Investigational Dermatology 2009:2 56
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non-dermatophyte infections. Despite its higher MIC to 
pathogenic yeast, topically administered terbinaﬁ  ne appeared 
effective for the management of tinea versicolor,166 and orally 
administered terbinaﬁ  ne (250 mg twice daily) has been used 
successfully for the treatment of cutaneous candidiasis.167 
Given, however, that the majority of superﬁ  cial Candida 
infections will respond to topical antifungals, the role of 
terbinaﬁ  ne in these infections remains unclear. A brief sum-
mary of additional non-dermatophyte infections wherein 
terbinaﬁ  ne has been utilized is provided in Table 3.
Adverse effects
Terbinafine has been extensively used with a relatively 
low incidence of reported adverse drug reactions. Clini-
cal trials evaluating the efficacy of orally administered 
terbinafine in both children and adults have noted adverse 
event rates in as high as 52%; however, less than 10% were 
attributed to the drug.165,182–184 Most terbinafine related 
adverse events are mild or moderate and include gastroin-
testinal complaints (eg, nausea, abdominal pain, vomiting, 
diarrhea), cutaneous eruptions, weight gain, appetite 
changes, headaches, and vertigo.43,152,165,185,186 Those adverse 
reactions involving the gastrointestinal system and skin 
are most commonly associated with discontinuation of 
therapy,165,186 with the risk of discontinuation estimated 
at 3.4%.187
Serious adverse drug reactions, most commonly involving 
the liver and the hematologic system, are only rarely reported 
with terbinaﬁ  ne use (0.04%).188 Hepatotoxicity ranging 
from mild transaminitis to fulminant liver failure has been 
Table 3 Case-reports and open-label studies examining terbinaﬁ  ne use in non-dermatophyte infections
Organism Site Dosing regimen Outcome Reference
Aspergillus spp. toenail 500 mg/day (pulse: 1 wk/mos) clinical and mycological 168
3 months cure (88%)
Aspergillus ﬂ  avus musclea 250 mg daily resolution 169
13 weeks
Aspergillus sydowii toenail 500 mg/day (pulse: 1 wk/mos)b failure 128
3 months
Aspergillus ustus skina not providedc resolution 170
11 months
Cladosporium carrionii skin 500 mg daily cure or clinical 171, 172
4–12 months improvement (83%–100%)
Curvularia lunata heart valve 125 mg twice dailyd,e tissue mycologically 173
(endocarditis) 7 years negative
Fonsecaea monophora skin 250 mg dailyb clinical and mycological 174
7–10 weeks cure
Fonsecaea pedrosoi skin 500 mg daily cure or clinical 171,172
4–12 months improvement (83%–100%)
Paecilomyces lilacinus cornea (keratitis) 250 mg once dailyb,c resolution 175, 176
10–12 weeks
Paracoccidoides brasiliensis perineum/scrotum 250 mg twice daily resolution 177
6 months
Piedra hortae scalp 250 mg once daily effective 178
6 weeks
Phialphora parasitica disseminateda 125 mg twice daily drug discontinued 179
2 months
Sporothix schenckii cutaneous/subcutaneous 250 mg twice daily success 180, 181
range: 8–37 weeks
Notes: aPatient immunocompromised or immunosuppressed; bConcurrent treatment with itraconazole; cConcurrent treatment with voriconazole; dConcurrent treatment 
with amphotericin B; eConcurrent treatment with ketoconazole.Clinical, Cosmetic and Investigational Dermatology 2009:2 57
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reported as a consequence of oral terbinaﬁ  ne use. It is 
estimated that 2.2% of patients treated with terbinaﬁ  ne will 
experience changes in their liver function tests.187 The onset 
typically occurs after 3 weeks of therapy and resolution can 
take as long as 3 months after discontinuation of the drug. 
While the majority of cases resolve following discontinu-
ation of terbinaﬁ  ne, reports are available detailing patients 
that have progressed to liver transplantation and death.189,190 
Notably, hepatic ﬁ  ndings are not restricted to adults. An 
FDA review of the recently marketed terbinafine oral 
granule identiﬁ  ed two cases, among 1042 children treated, 
of elevated transaminases leading to discontinuation of the 
drug.191 Terbinaﬁ  ne-induced acute autoimmune hepatitis 
has also been reported in a patient infected with hepatitis B 
virus.192,193
Blood dyscrasias including leucopenia, agranulocytosis, 
neutropenia and pancytopenia represent the other primary 
group of severe adverse drug reactions reported with 
terbinaﬁ  ne use. Most cases occur between weeks 4 to 5 
of therapy and resolve within a week after stopping the 
medication. One fatality has been reported in a 79-year-old 
female who developed septic shock while being treated for 
terbinaﬁ  ne induced agranulocytosis.194 Among children 
receiving the new granule formulation, leucopenia and/or 
neutropenia was observed in 1.8% (19/1042) of the children 
treated.191
Severe dermatologic eruptions including toxic epider-
molysis, acute generalized exanthematous pustulosis, and 
Steven’s Johnson syndrome have also been associated 
with terbinaﬁ  ne use.195 Recently, reports have also linked 
dermatomyositis and subacute cutaneous systemic lupus 
erythematosus to terbinaﬁ  ne.196,197 In one patient, a skin 
eruption presenting 4 weeks after the onset of therapy and 
occurring with the triad of fever, hepatic dysfunction and 
lymphadenopathy led investigators to conclude the presence 
of hypersensitivity syndrome. Resolution was experienced 
within 6 weeks of discontinuing the drug.198–203
An adverse effect unique to terbinafine is altered 
taste perception. Although numerous case reports have 
been published, there exist no reliable estimates of this 
side effect in patients taking terbinaﬁ  ne.204–210 Ageusia 
has taken up to 6 weeks to resolve, and was reported in 
association with loss of smell and discoloration of the 
tongue, in one patient each.208,210 Possible risk factors for 
developing terbinaﬁ  ne associated taste loss include an 
age greater than 65 years and a body mass index less than 
21 kg/m2.211 Notably, a singular trial comparing terbinaﬁ  ne 
with griseofulvin for the treatment of tinea capitis, reported 
a change of eating habits in 4.7% and 5.5% of children, 
respectively. Whether, however, this was due to changes 
in taste perception is unknown.165
Of note, fewer patients receiving terbinaﬁ  ne pulse therapy 
as compared with traditional dosing experience elevations 
in liver enzymes or taste disturbances; however, the overall 
percentage of patients discontinuing therapy for adverse 
events was comparable between dosing strategies.124
While only a few reports exist, ocular side effects have 
been observed with oral terbinaﬁ  ne use.212–214 Bilateral 
anterior optic neuropathy with decreased vision and 
optic disc edema was reported in a patient 2 weeks after 
starting terbinaﬁ  ne (500 mg/day).214 After discontinuing 
the medication his vision improved. Anterior uveitis 
was reported in a second patient with acquired immune 
deﬁ  ciency syndrome after 12 days of therapy. As in the 
previous case, symptoms resolved with discontinuation 
of terbinaﬁ  ne.213
Among patients treated with topical terbinaﬁ  ne prepa-
rations, adverse events are primarily restricted to mild to 
moderate local skin reaction which may occur in as many 
as 6% of patients.99
Conclusions
Terbinaﬁ  ne is among the most commonly used antifungal 
agents for the treatment of dermatophyte infections of the 
skin and nails. The success experienced by this drug can, 
in large part, be attributed to its favorable mycologic and 
pharmacokinetic proﬁ  les. Terbinaﬁ  ne possesses many of the 
characteristics required of a drug used for infections where 
clinical resolution is largely dependent on the slow turnover 
of infected tissue, namely, excellent penetration at the site 
of infection and sustained fungicidal activity for extended 
durations after the discontinuation of therapy. Numerous 
clinical trials corroborate the suitability of terbinaﬁ  ne 
for the treatment of dermatophytoses with efﬁ  cacy rates 
comparable to or greater than existing antifungals despite 
shorter treatment durations. While the role of terbinaﬁ  ne 
use in systemic mycoses has been limited to date, the agent 
may eventually ﬁ  nd utility as an adjunctive agent in the 
management of recalcitrant infections. Although terbinaﬁ  ne 
is likely to remain the ﬁ  rst-line agent for a number of der-
matophyte infections, prescribers should remain cognizant 
of the infrequent but severe adverse reactions that have 
been observed (eg, agranulocytosis, hepatotoxicity) and 
the potential for signiﬁ  cant drug–drug interactions with 
medications that rely on CYP2D6 as a primary route of 
metabolism.Clinical, Cosmetic and Investigational Dermatology 2009:2 58
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